Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shuta Tomida

Showing results (121-130 of 169) with videos related to

Pageof 17
Sort By:
Cancer|October 22, 2015
Clinicopathological and genetic differences between low-grade and high-grade colorectal mucinous adenocarcinomasYasumasa Yoshioka, Yosuke Togashi, Takaaki Chikugo, et al.
Cancer Medicine|August 4, 2025
Real-World Data of Comprehensive Cancer Genomic Profiling Tests Performed in the Routine Clinical Setting in SarcomaEiji Nakata, Daisuke Ennishi, Tatsunori Osone, et al.
International Journal of Proteomics|June 8, 2012
Seven-signal proteomic signature for detection of operable pancreatic ductal adenocarcinoma and their discrimination from autoimmune pancreatitisKiyoshi Yanagisawa, Shuta Tomida, Keitaro Matsuo, et al.
Cancer Research Communications|March 11, 2026
Constitutive EGFR activation induced by PTPRR downregulation confers resistance to KRAS inhibitorsHiroaki Kanemura, Toshiyuki Takehara, Osamu Maenishi, et al.
Scientific Reports|June 24, 2021
Reduced dose of PTCy followed by adjuvant α-galactosylceramide enhances GVL effect without sacrificing GVHD suppressionMakoto Nakamura, Yusuke Meguri, Shuntaro Ikegawa, et al.
Molecular Cancer Therapeutics|May 29, 2025
Colony-Stimulating Factor-1 Receptor Inhibitor Augments Osimertinib-Induced Antitumor Immunity via Suppression of Macrophages in Lung Cancer Harboring EGFR MutationSachi Okawa, Shuta Tomida, Tadahiro Kuribayashi, et al.
Cancer Research Communications|January 13, 2026
Clinical characteristics and spatial transcriptome analysis of non-small cell lung cancers exhibiting early alectinib resistance: a retrospective OLCSG studyTadahiro Kuribayashi, Go Makimoto, Kadoaki Ohashi, et al.
Biochemical and Biophysical Research Communications|August 2, 2020
Overcoming epithelial-mesenchymal transition-mediated drug resistance with monensin-based combined therapy in non-small cell lung cancerKosuke Ochi, Ken Suzawa, Shuta Tomida, et al.
Scientific Reports|May 4, 2022
One-step nucleic acid amplification for intraoperative diagnosis of lymph node metastasis in lung cancer patients: a single-center prospective studyKei Namba, Ken Suzawa, Kazuhiko Shien, et al.
Molecular Cancer Therapeutics|September 26, 2014
MEK inhibitor for gastric cancer with MEK1 gene mutationsShunsuke Sogabe, Yosuke Togashi, Hiroaki Kato, et al.
Pageof 17

Showing results (121-130 of 169) with videos related to

Sort By:
Pageof 17
Cancer|October 22, 2015
Clinicopathological and genetic differences between low-grade and high-grade colorectal mucinous adenocarcinomasYasumasa Yoshioka, Yosuke Togashi, Takaaki Chikugo, et al.
Cancer Medicine|August 4, 2025
Real-World Data of Comprehensive Cancer Genomic Profiling Tests Performed in the Routine Clinical Setting in SarcomaEiji Nakata, Daisuke Ennishi, Tatsunori Osone, et al.
International Journal of Proteomics|June 8, 2012
Seven-signal proteomic signature for detection of operable pancreatic ductal adenocarcinoma and their discrimination from autoimmune pancreatitisKiyoshi Yanagisawa, Shuta Tomida, Keitaro Matsuo, et al.
Cancer Research Communications|March 11, 2026
Constitutive EGFR activation induced by PTPRR downregulation confers resistance to KRAS inhibitorsHiroaki Kanemura, Toshiyuki Takehara, Osamu Maenishi, et al.
Scientific Reports|June 24, 2021
Reduced dose of PTCy followed by adjuvant α-galactosylceramide enhances GVL effect without sacrificing GVHD suppressionMakoto Nakamura, Yusuke Meguri, Shuntaro Ikegawa, et al.
Molecular Cancer Therapeutics|May 29, 2025
Colony-Stimulating Factor-1 Receptor Inhibitor Augments Osimertinib-Induced Antitumor Immunity via Suppression of Macrophages in Lung Cancer Harboring EGFR MutationSachi Okawa, Shuta Tomida, Tadahiro Kuribayashi, et al.
Cancer Research Communications|January 13, 2026
Clinical characteristics and spatial transcriptome analysis of non-small cell lung cancers exhibiting early alectinib resistance: a retrospective OLCSG studyTadahiro Kuribayashi, Go Makimoto, Kadoaki Ohashi, et al.
Biochemical and Biophysical Research Communications|August 2, 2020
Overcoming epithelial-mesenchymal transition-mediated drug resistance with monensin-based combined therapy in non-small cell lung cancerKosuke Ochi, Ken Suzawa, Shuta Tomida, et al.
Scientific Reports|May 4, 2022
One-step nucleic acid amplification for intraoperative diagnosis of lymph node metastasis in lung cancer patients: a single-center prospective studyKei Namba, Ken Suzawa, Kazuhiko Shien, et al.
Molecular Cancer Therapeutics|September 26, 2014
MEK inhibitor for gastric cancer with MEK1 gene mutationsShunsuke Sogabe, Yosuke Togashi, Hiroaki Kato, et al.
Pageof 17